^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19/BCMA targeted CAR T-cells
i
Other names: CD19/BCMA targeted CAR T-cells, CD19/BCMA-targeted CAR-T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Yake Biotech
Drug class:
CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
Related drugs:
1year
CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study (ASH 2023)
After lymphodepleting chemotherapy with cyclophosphamide/fludarabine (D-4 to D-2), patients receive a single infusion of 1-2x106 CD19 CAR-T cells and BCMA CAR-T cells per kilogram of body weight at D0...All patients had active severe SLE and had received glucocorticoids, hydroxychloroquine, tacrolimus, total glucosides of paeony, merti-macrolide, leflunomide, azathioprine, methotrexate, cyclophosphamide, immunoglobulin, rituximab, belimumab, and Tetracycline before treatment with CAR-T cells, which were standard treatments that were either ineffective or difficult to withdraw.3 patients received 1x10^6/kg of each of CD19 CAR-T cells and BCMA CAR-T cells, and 9 patients received 2x10^6/kg of each of CD19 CAR-T cells and BCMA CAR-T cells 2x10^6/kg... These data suggest that CD19/BCMA CAR-T cell therapy is well tolerated and can induce rapid and durable remission in severe refractory SLE.
Clinical • P1 data • CAR T-Cell Therapy
|
Rituxan (rituximab) • cyclophosphamide • methotrexate • hydroxychloroquine • fludarabine IV • CD19/BCMA targeted CAR T-cells • leflunomide
4years
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies (clinicaltrials.gov)
P1, N=120, Recruiting, Zhejiang University
Clinical • New P1 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
dasatinib • BCMA targeted CAR T-cells • CD19/BCMA targeted CAR T-cells
Share via
